Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma Moderna has completed regulatory submissions for mRNA-1273.214 in EU, UK, and Australia, expects to complete most remaining filings this week Company simultaneously developing mRNA-1273.222, a bivalent candidate based on BA.4/5, consistent with recent FDA guidance CAMBRIDGE, MA / ACCESSWIRE / July 11, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited significantly higher neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 compared to the currently authorized booster (mRNA-1273) regardless of prior infection status or age (adults over 18, greater or less than 65 years old).

Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster

Our Speculative Buy rating on Moderna stock has played out accordingly and reached our near-term price target. Therefore, investors are urged to pay attention to price action for helpful clues. Notwithstanding, we believe the risk/reward profile is no longer attractive to add exposure. Investors should consider layering out.

Moderna: Attacked The Pessimism With Aplomb (Technical Analysis)

Moderna Inc (NASDAQ: MRNA) shares are trading higher Thursday amid rising monkeypox concerns.  According to a Reuters report citing the country's Public Health Authority, Slovakia confirmed its first case of monkeypox today.

What's Going On With Moderna Stock?

The biotech is benefiting from the broader market's gains.

Why Moderna Stock Is Surging Today

There's still significant risk associated with investing in this vaccine stock.

Is Moderna Stock a No-Brainer Buy With Omicron Boosters on the Way?

Diamondback Energy

Goldman Sachs

The depressed P/E ratios of these three S&P 500 growth stocks make them value stocks in a growth wrapper—and bargain buys for investors.

3 Growth Stocks Trading at Value P/E's

Moderna (MRNA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Moderna (MRNA) Keep the Earnings Surprise Streak Alive?

BioNTech SE

Pfizer

In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.

FDA Recommends Adding New Omicron Subvariants to COVID Boosters

The healthcare stock last hit the $400 mark in September.

Could This Send Moderna's Stock Soaring Back to $400?

The FDA's VRBPAC committee recommends updated COVID-19 vaccine boosters that target the Omicron variant to improve vaccine effectiveness.

FDA Panel Recommends Modifying COVID Jabs to Target Omicron

Biogen

Gilead Sciences

Halozyme Therapeutics

IQVIA Hlds

United Therapeutics

Biotech stocks have suffered significant setbacks during the first half of the year but are likely to bounce back soon The post 7 Biotech Stocks With Key Catalysts Coming in July appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn't matter if you have $500 in savings or $5 million.

7 Biotech Stocks With Key Catalysts Coming in July

Moderna's vaccine is now available for almost everyone.

Could This Be Moderna's Ticket to Long-Term Success?

Why Many parents are concerned about the effect of the coronavirus pandemic on their children.

Why Pfizer and Moderna Would Profit As CDC Recommends Covid Vaccine For Toddlers

Moderna is ready to step back into the limelight.

1 Green Flag for Moderna's Fall Vaccine Plan, and 1 Red Flag

A panel of advisers to the Centers for Disease Control and Prevention voted unanimously Thursday to recommend Moderna's COVID vaccine for children and adolescents aged 6 to 17.

CDC panel backs Moderna vaccine for children aged 6 to 17, and study finds vaccines saved about 20 million lives in their first year

CDC Director Dr. Rochelle Walensky is expected to sign off on the recommendation later Thursday,.

CDC panel recommends Moderna two-dose Covid vaccine for kids ages 6 to 17

Moderna's (MRNA) bivalent COVID booster candidate exhibits a greater than a 5-fold boost in antibody responses against the Omicron subvariants BA.4 and BA.5 in a phase II/III study.

Moderna (MRNA) Reveals New Data on Bivalent COVID Booster

Moderna's Chief Executive Stephane Bancel said the company's COVID-19 variant vaccine would be ready to ship in August, saying the bottleneck supply was regulatory.

Moderna CEO: COVID variant vaccine to be ready for shipping in August

Moderna Inc (NASDAQ: MRNA) shares are trading higher after the company released data on its bivalent COVID booster candidate. Data showed potent neutralizing antibody responses against the omicron subvariants BA.4 and BA.5.

So What's Going On With Moderna Shares Rising Today?

COVID cases are again surging in Europe, driven by the BA.4 and BA.5 subvariants of omicron that are deemed to be 10% to 15% more infectious than earlier variants and are spreading fast in Portugal, France, Germany, Italy, Spain, Greece, the Netherlands and Denmark.

COVID cases surge again in Europe and Moderna says booster candidate protects against BA.4 and BA.5 omicron subvariants

Moderna Therapeutics Inc (NASDAQ:MRNA) has announced plans to open its first vaccine factory in the UK, praising Britain's "world-class life sciences and research community" efforts during COVID-19. A deal worth £1bn will see the vaccine manufacturer collaborate with the UK government to build a manufacturing facility for messenger RNA vaccines for COVID and flu.

Moderna to open new vaccine factory in the UK

The company is hoping to offer the booster shot, which targets both omicron and the original coronavirus strain, in the fall.

Moderna's Covid Booster Shot Produces Strong Antibodies Against Fast-Spreading Omicron Subvariants

Moderna Inc. MRNA, +1.53% said it shared new data with regulators about its bivalent COVID-19 booster's antibody response against the BA.4 and BA.5 subvariants as it seeks to update its authorized booster with the new formulation. Moderna's bivalent booster protects against both omicron and the original strain of the virus.

Moderna's bivalent booster also protects against BA.4 and BA.5 subvariants

mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study Data Being Submitted to Regulators and for Peer Reviewed Publication CAMBRIDGE, MA / ACCESSWIRE / June 22, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent (Omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 in all participants regardless of prior infection.

Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5

Manufacturing facility would provide access to domestically manufactured vaccines against respiratory viruses Moderna would expand its presence in the UK through investments in R&D activities and capabilities Collaboration would support the UK with direct access to rapid pandemic response capabilities CAMBRIDGE, MA / ACCESSWIRE / June 21, 2022 / Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement in principle with the United Kingdom government to establish an mRNA Innovation and Technology Center in the UK.

News for Moderna Stock (MRNA)